Peptide Research & Science: Clinical Trials, Studies & News
Where peptide science stands right now — clinical trial updates, new compound developments, FDA regulatory news, and evidence-based analysis of emerging research.
Key Takeaway
This guide covers everything you need to know about peptide research and science. From how clinical trials work to evaluating study quality, this is your reference for understanding the evidence behind peptides.
Pipeline Compounds to Watch
Next-generation weight loss peptides currently in clinical trials:
- Retatrutide (Eli Lilly) -- Triple agonist (GLP-1/GIP/glucagon). Phase 2 showed 24.2% weight loss. Phase 3 ongoing.
- Survodutide (Boehringer Ingelheim) -- GLP-1/glucagon dual agonist. ~18.7% weight loss in Phase 2. Notable liver fat reduction.
- Orforglipron (Eli Lilly) -- Oral GLP-1 small molecule. ~14.7% weight loss in Phase 2. No injections required.
- CagriSema (Novo Nordisk) -- Semaglutide + amylin analog. ~22.7% weight loss in Phase 3. Two satiety pathways.
How to Evaluate Research
Not all studies carry the same weight. Our evidence hierarchy:
- Phase 3 RCTs (1,000+ participants) -- the gold standard
- Phase 2 RCTs (100-500 participants) -- strong signal, needs confirmation
- Animal/in vitro studies -- preliminary, not human evidence
- Anecdotal reports -- useful for hypothesis generation, not for decisions
Key Resources
- PubMed -- peer-reviewed medical literature
- ClinicalTrials.gov -- registered trial data
- FDA.gov -- approval status and safety alerts
Compounds in Development
Frequently Asked Questions
What new weight loss peptides are in clinical trials?
As of 2026, retatrutide (triple agonist, Eli Lilly), survodutide (dual agonist, Boehringer Ingelheim), orforglipron (oral GLP-1, Eli Lilly), and CagriSema (semaglutide + cagrilintide, Novo Nordisk) are all in Phase 2 or Phase 3 trials. Retatrutide showed up to 24.2% body weight loss in Phase 2.
How do you evaluate peptide research quality?
Look for: peer-reviewed publication in indexed journals, PubMed listing with PMID, adequate sample size, human (not just animal) data, randomized controlled trial design, and independent funding. Be cautious with pre-prints, conference abstracts, and industry-funded studies without independent replication.
What is the FDA doing about peptides in 2026?
What does research-only status mean?
Research-only means a peptide has not completed the FDA approval process for human therapeutic use. It may have animal studies, preliminary human data, or early-phase clinical trials, but it is not an approved medication. Research-only peptides are sold for laboratory research purposes.
Where can I find peptide clinical trial data?
ClinicalTrials.gov lists all registered trials. PubMed (pubmed.ncbi.nlm.nih.gov) indexes published study results. Each peptide profile on this site links directly to relevant PubMed studies with PMID numbers for verification.
This content is for educational and informational purposes only. It is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol. See our full medical disclaimer.